A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)

Inclusion Criteria: * Established clinical diagnosis of type 1 diabetes, consistent with ADA classification criteria (Diabetes Care 35: S64-S71, 2012), for more than 1 year. * Age: 18 years old, or older. * Body Mass Index: between 18 and 35 kg/m2, inclusive. * Willing to use insulin glargine as the only basal insulin throughout the duration of the trial. * Willingness not to use insulin pump treatment and only use the study glucose meter and CGM devices during the duration of the trial. Exclusion Criteria: * History of known hypersensitivity to any of the components in the study medication * Treatment with pramlintide or GLP-1 analogs within 30 days of screening or anticipated use of these medications during the course of the study. * Treatment with oral or intravenous corticosteroids in the last 3 months prior to screening. Standard doses of inhalational corticosteroid used as part of a long term treatment regimen are allowed. * Consistent recent hypoglycemic unawareness within the last six months * History of more than two severe hypoglycemic events within six months prior to screening